Aarti Drugs Limited
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations.
What Aarti files
- Others64
- Investor Meet39
- Updates15
- Important12
- Board Meeting10
- PPTs6
Aarti Drugs kicked off FY27 with a solid Q1 performance. Revenue climbed 19% YoY to Rs. 704 Cr, fueled by higher volumes and improved pricing in API & Specialty Chemicals. EBITDA surged 30% to Rs. 97 Cr, with margins expanding to 13.8%, while PBT rose 35% to Rs. 69 Cr....
Here's a concise, retail-friendly summary: Aarti Drugs delivered solid FY26 results, with revenue up 7% to Rs. 2,568 Cr and Profit After Tax climbing 16% to Rs. 195 Cr (EPS Rs. 21.36). Q4 FY26 also showed resilience, with revenue growing 6% YoY to Rs. 721 Cr and strong sequential recovery...
Here's a concise summary for Aarti Drugs Limited: **1. Business Performance:** Aarti Drugs reported steady Q3 FY26 results with total revenue up 8% YoY to ₹603 Crore. While EBITDA saw a 10% YoY dip to ₹56 Crore (margin 9.3%), Net Profit (PAT) surged 58% YoY to ₹41 Crore (margin 6.7%),...
**Financial Highlights:** Aarti Drugs' Q1 FY26 revenue grew 6% to ₹591 Cr. Profit After Tax soared 63% to ₹54 Cr. EBITDA rose 13% to ₹74 Cr (12.6% margin). Gross margins expanded to 36.8%, reflecting improved API demand and volume recovery. **Strategic Initiatives & Growth Drivers:** The company is executing its...
1. Financial Highlights: Aarti Drugs posted Q4 revenue of Rs. 677 Cr, up 9% YoY, with EBITDA at Rs. 95 Cr (+10%) and margin steady at 14%. PAT rose 33% to Rs. 63 Cr, margin improving to 9.2% from 7.6%. For FY25, revenue declined 5% to Rs. 2,403 Cr due...